VANCOUVER, BC — February 27, 2026 — Leads & Copy — BioNxt Solutions Inc. has announced the issuance of 6,008,883 common shares to settle $2,704,000 in debt.
The debt settlement, previously announced on January 23, 2026, involved issuing shares at a deemed price of $0.45 per share.
The settled debt included a principal amount of $2,600,000 and $104,000 in accrued interest from 8% convertible debentures issued on December 7, 2022.
In facilitating the debt settlement, BioNxt issued 300,444 common shares to Canaccord Genuity Corp. The compensation shares were priced at $0.63 each.
The debt shares and compensation shares are subject to a statutory four-month and one-day hold period, adhering to Canadian securities laws.
BioNxt Solutions Inc. focuses on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The company utilizes proprietary platforms like Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets) to target therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. BioNxt has research and development operations in North America and Europe and is focused on regulatory approvals and commercialization efforts, primarily in European markets.
BioNxt is listed on the Canadian Securities Exchange under the symbol BNXT, on the OTCQB Markets under the symbol BNXTF, and in Germany under WKN: A3D1K3.
THIS NEWS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF ANY OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL. THE SHARES ISSUED HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “U.S. SECURITIES ACT”) AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.
Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Source: BioNxt Solutions Inc.
